Phaseline

Companies › Artiva Biotherapeutics

Artiva Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Immunology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AlloNK
Allogeneic non-genetically modified cord blood-derived NK cell therapy
–Phase 2Refractory Rheumatoid Arthritis (RA)Jan 2028
AB-101
Allogeneic natural killer (NK) cell therapy
–Phase 1Lupus Nephritis - WHO Class IIIAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06265220AB-101Phase 1Lupus Nephritis - WHO Class IIIImmunologyAug 2027
NCT06991114AlloNKPhase 2Refractory Rheumatoid Arthritis (RA)ImmunologyJan 2028

From the company's SEC filings

Cash and short-term investments of $319m on 2026-09-30; operating cash outflow about $94m a year; runway about 41 months at that burn, to Feb 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cellcolabs Clinical SPV EHL Bio Nature Cell Throne Biotechnologies Xentria

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.